KartRider: Drift Races Into Its Inaugural Season With Console Cross-play Date Reveal
KartRider: Drift , Nexon’s completely free-to-play kart racing title, announced today its Season One date when consoles will join the online racing mix. Current Preseason PC and mobile racers on Steam, Nexon Launcher, Android, and iOS, will soon be able to compete head-to-head against Xbox and PlayStation players from all over the globe in thrilling, drift-fueled racing. Full cross-platform, cross-play will be available when Season One “New World” arrives on March 8. Season One also brings with it exciting new content – brand new tracks and race modes, a season-long theme, daily player rewards and events, plus many other improvements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005459/en/
Nexon's "KartRider: Drift" Announces March 8 Season One Arrival Date With New Gameplay Trailer. (Graphic: Business Wire)
KartRider: Drift isn’t as simple as it may seem! The easy-to-learn, hard-to-master game offers distinct game modes designed to train and challenge new and veteran racers:
- In Item Mode, various offensive and defensive items (such as shields, barricades, and nitrous boosts) are collected and can then be strategically deployed to help or hinder other racers on the track in an attempt to cross the finish line first.
- Speed Mode puts the racer's drifting skills to the test with no-holds-barred arcade racing and no items to slow racers down. The fastest racer claims the trophy at the podium!
- The License System is a series of courses designed to test a racer's mettle and raise a player's skill level. Completing License challenges unlocks unique player items such as karts, characters, and additional tracks.
- In Time Attack Mode, solo racers can push their skills to the limit to top the leaderboards.
With a dazzling array of unique characters and karts, KartRider: Drift players have complete control over customization options to express themselves fully and cross the finish line in style! More characters, karts, accessories, and emotes can be unlocked via the standard Racing Pass, where racers can complete different daily challenges and event challenges. New premium challenges and rewards are also available with the purchase of a Premium Racing Pass.
While still in Preseason, KartRider: Drift continues to add improvements and make adjustments to the core game experience based on player feedback in an upcoming February 15 game update. Update details will be available on the KartRider: Drift site as the date approaches.
Be sure to follow the official Twitter and TikTok for all the latest game update news and information. KartRider: Drift is available to download and play now on Steam, Nexon Launcher, iOS App Store, and Google Play, and will be available for download on PlayStation and Xbox stores on March 8.
Don’t be left at the starting line – download KartRider: Drift and get YOUR race on!
NOTES FOR EDITORS:
All player progress earned during KartRider: Drift’s Preseason will carry over to Season One.
Nexon’s KartRider Rush+ mobile racing game, launched in 2020, will continue to operate as a standalone title and does not share cross-play with KartRider: Drift.
Social Media: Twitter / TikTok / Twitch / Discord / YouTube / Instagram / Facebook
About KartRider: Drift
KartRider: Drift is Nexon’s multiplayer kart racing party game, taking inspiration from earlier titles in the phenomenally successful KartRider franchise, delivering drift-fueled racing action, featuring multiple game modes and deep kart and character customization in stunning Unreal® Engine 4 graphics. Available on Steam, the Nexon Launcher, mobile (iOS and Android) during Preseason, and with Xbox and PlayStation consoles joining at the launch of Season One, KartRider: Drift offers free-to-play, online cross-platform play and progression to challenge friends regardless of the platform they choose.
Launched in 2004, the original KartRider was the first title in Nexon’s legendary kart racing series, and subsequently gained huge popularity in Asia and beyond, amassing more than 380 million players during the nineteen years since release. As a franchise, KartRider has established a strong brand across Asian markets and a huge eSports presence in Asia, with an official league starting in 2005. It continues to be the longest-running eSports league to date.
About Nexon America Inc.
Founded in 2006, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005459/en/
Contact information
Brian Klotz, Nexon America
NA_pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom